Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.55 |
| ▸ | JAK2 | O60674 | 6/20 | 0.54 |
| ▸ | JAK3 | P52333 | 5/20 | 0.54 |
| ▸ | TYK2 | P29597 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385653 | 0.85 | JAK1 (0.74) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL2280456 | 0.85 | JAK1 (0.74) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL16477603 | 0.85 | JAK1 (0.71) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL18419770 | 0.84 | JAK1 (0.60) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14708588 | 0.84 | JAK1 (0.60) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL15944817 | 0.84 | JAK1 (0.55) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL14708096 | 0.78 | JAK3 (0.74) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14708370 | 0.78 | JAK3 (0.74) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12385594 | 0.72 | JAK1 (0.61) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL2280767 | 0.72 | JAK1 (0.61) | JAK1JAK2JAK3TYK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123167-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | 日産化学工業株式会社 (JP) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.